Elli Malakounidou

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

N/A

0Author DataRank · unranked

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 1 paper. Top paper: “Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial”.

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial

Clinical Microbiology and Infection(2023)10.1016/j.cmi.2022.10.015

N/A

0.574DataRank · unranked

45 citations

Ourania Papaioannou, Panagiota Tsiri, Matthaios Katsaras, Andreas Katsimpris, Andreas P. Kalogeropoulos +14 more